Author, as appears in the article.: Pena, Karla B.; Kepa, Amillano; Cochs, Alba; Riu, Francesc; Parada, David; Guma, Josep;
Department: Medicina i Cirurgia
URV's Author/s: Gumà Padró, José / Parada Dominguez, David / Peña Gonzalez, Karla Beatriz / Riu Ferrando, Francisco Pedro
Keywords: Very elderly Tumor volume Tumor marker Tumor burden Trastuzumab Total tumor load Technetium 99m Taxane derivative Surgery Sentinel lymph node biopsy Sentinel lymph node Rna, messenger Prospective studies Predictive value of tests Predictive value Pertuzumab Pathology Paget nipple disease Paclitaxel Osna Nucleic acid amplification Neoadjuvant therapy Neoadjuvant chemotherapy Middle aged Messenger rna Mastectomy Major clinical study Lymphatic metastasis Lymph node metastasis Lymph node excision Lymph node dissection Krt19 protein, human Keratin-19 Humans Human tissue Human Gold standard Genetics Gene dosage Female Doxorubicin Docetaxel Diagnostic test accuracy study Diagnostic accuracy Descriptive research Cytokeratin 19 Cyclophosphamide Correlational study Controlled study Cohort analysis Cell isolation Carcinoma, ductal, breast Carcinoma cell Carboplatin Cancer size Cancer patient Cancer adjuvant therapy Breast tumor Breast neoplasms Breast carcinoma Breast cancer Breast Biomarkers, tumor Axillary lymphadenectomy Axillary lymph node dissection Axilla Article Antineoplastic agent Anthracycline derivative Aged, 80 and over Aged Adult Adjuvant therapy
Abstract: Although sentinel lymph node biopsy (SLNB) has proved to be able to diagnose axillary lymph node status safely and reliably, there is still not enough evidence to suggest that it can be used in patients who have undergone neoadjuvant chemotherapy (NAC) for lymph node-sparing surgery. The present study used molecular approaches to determine whether SLNB can be reliably used in patients who have been treated with NAC before SLN surgery, and whether the total tumor load of the SLN can be used as a predictive factor in axillary lymphadenectomy (ALD). We used one-step nucleic acid amplification (OSNA) to analyze a total of 111 consecutive patients who presented operable invasive breast carcinomas and who had been treated with NAC. SLN was positive in 55 patients and the identification rate was 100%. In 9 of these 55 patients, ALD showed that other lymph nodes were also involved. In all of the other 46 patients, the only lymph node to be identified as positive was SLN. Metastasis was not found in any of the axillary lymph nodes in the isolated tumor cell group. The total tumor load, defined as the amount of cytokeratin 19 mRNA copy numbers in all positives SLN (copies/mu L), showed three risk groups related to the possibility of positive non-sentinel nodes. OSNA is a diagnostic technique that is highly sensitive, specific, and reproducible and it can be used to analyze sentinel lymph nodes after NAC. Total tumor load may be able to help predict additional metastases in axillary lymphadenectomy.
Thematic Areas: Medicina ii Medicina i Matemática / probabilidade e estatística Genetics (clinical) Genetics & heredity Genetics Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência da computação Biotecnología Biodiversidade
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: franciscopedro.riu@urv.cat karlabeatriz.pena@urv.cat david.parada@urv.cat jose.guma@urv.cat
Author identifier: 0000-0001-7541-9832
Record's date: 2024-07-27
Papper version: info:eu-repo/semantics/publishedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Genes. 12 (1): 1-10
APA: Pena, Karla B.; Kepa, Amillano; Cochs, Alba; Riu, Francesc; Parada, David; Guma, Josep; (2021). Total Tumor Load of mRNA Cytokeratin 19 in the Sentinel Lymph Node as a Predictive Value of Axillary Lymphadenectomy in Patients with Neoadjuvant Breast Cancer. Genes, 12(1), 1-10. DOI: 10.3390/genes12010077
Entity: Universitat Rovira i Virgili
Journal publication year: 2021
Publication Type: Journal Publications
Repositori URV